Notizie AIOM – anno XV
ASCO Releases Position Statement on Access to Investigational Drugs
April 25, 2017 - ASCO strongly supports increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal “right-to-try” legislation as well as state-enacted right-to-try laws. ...Leggi tutto
FDA Grants Lorlatinib Breakthrough Designation for NSCLC
April 27, 2017 - The FDA has granted a breakthrough therapy designation to lorlatinib for use in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have previously received 1 or more ALK inhibitors, according to Pfizer, the company developing the ...Leggi tutto
EU Grants Full Approval to Osimertinib for EGFR T790M-Positive NSCLC
April 26, 2017 - The European Union (EU) has granted a full approval to osimertinib for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer (NSCLC), regardless of prior treatment with an EGFR TKI. This ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore dello stomaco è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due ...Leggi tutto
FDA Schedules ODAC Meeting for Neratinib in HER2+ Breast Cancer
April 17, 2017 - The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for May 24, 2017, to discuss a new drug application (NDA) for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, ...Leggi tutto
FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers
April 18, 2017 - On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Atezolizumab was ...Leggi tutto
FDA Grants CTL019 Breakthrough Designation for DLBCL
April 18, 2017 - The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after the failure of at least 2 prior therapies, according to Novartis, ...Leggi tutto
Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer
Two previous single-arm trials have drawn conflicting conclusions regarding the activity of pazopanib in urothelial cancers after failure of platinum-based chemotherapy. This randomized (1:1) open-label phase II trial compared the efficacy of pazopanib 800 mg orally with ...Leggi tutto